



Atty Dkt No. ARC 2865N1
USSN: 09/802,709
PATENT

Hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 24, 2002

May 24, 2002
Date

Signature

Maia E. Valenzuela

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lam, et al
Serial No: 09/802,709
Filed: 03/08/2001
For: METHODS AND DEVICES
FOR PROVIDING
PROLONGED DRUG
THERAPY

Group Art Unit: 1614
Examiner: FAY, Z.

Letter

Letter

Honorable Commissioner of
Patents and Trademarks
Washington, D. C. 20231

Madam:

Applicants received a Notice of Abandonment dated December 19, 2001 regarding the above-identified patent application stating the Applicant's failed to timely file a proper reply to the Office Action mailed on May 29, 2001.

Applicants subsequently received an Office Communication dated May 7, 2002 regarding the above-identified patent application stating that "the amendment filed January 9, 2002 canceling all claims drawn to the elected invention and presenting only claims drawn to a non-elected invention is non-responsive."

Attached hereto is a copy of the original documents filed in response to the May 29, 2001 Office Action, which were mailed to the U.S.P.T.O. on November 29, 2001, and are as follows:

TECH CENTER 1600/2900

JUN 24 2002

RECEIVED

#125
09/10
7-12-02

1. Return Receipt Postcard date stamped by the U.S.P.T.O. on January 9, 2002
2. Request for Extension of Time (1 page) (in duplicate)
3. Amendment Transmittal Letter (1 page)
4. Amendment (4 pages)
5. Certificate of Mailing by First Class Mail (1 page)
6. Courtesy Copy of Preliminary Amendment filed March 8, 2001 (5 pages)
7. Revocation and New Power of Attorney (2 pages)

Applicants did not cancel any further claims in the November 29, 2001 response to the Office Action and Applicants are unaware of any further amendment "filed January 9, 2002" other than the attached response.

Conclusion

Applicants respectfully request that the Notice of Abandonment be withdrawn and await allowance or Office Action responsive to Applicant's November 29, 2001 response.

Please direct any questions to the undersigned at (650) 564-5171.

Respectfully submitted,

Date: May 24, 2002

By: Robert R. Neller
Robert R. Neller
Registration No. 46,950

Address: ALZA Corporation
1900 Charleston Road M-10
Mountain View, CA 94043
Tel: 650-564-5171
Fax: 650-564-2195



RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

Box	ARC No. 2865N1
Director of the USPTO Washington, D.C. 20231	Date Mailed November 29, 2001
Applicant(s) Lam et al	
Serial No. 09/802,709	Filing Date 03/08/01
Examiner Z. Fay	Group Art Unit 1614
Documents received in this office	
Response to Amendment - 4 pp	
Request for Extension of Time - 1 p in duplicate	
Acknowledgement Postcard	
Amendment Transmittal Letter - 1 p	
Certificate of Mailing by First Class Mail - 1 p	
Courtesy Copy Preliminary Amendment filed March 8, 2001 - 5 pp	
Revocation, Power of Attorney - 2 pp	
Attorney PBS / KMG	Director of the USPTO

DOCKETED

JAN 23 2002

BY: _____

RECEIVED

JAN 21 2002

PATENT DEPT.



RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

DOCKETED

DFC - 3 2001

BY: _____

Box _____ ARC No. 2865N1

Director of the USPTO
Washington, D. C. 20231

Date Mailed: November 29, 2001

Applicant(s) Lam et al

Serial No. 09/802,709

Filing Date 03/08/01

Examiner Z. Fay

Group Art Unit 1614

Documents received in this office

- ✓ Response to Amendment - 4 pp
- ✓ Request for Extension of Time - 1 p. in duplicate
- ✓ Acknowledgement Postcard
- ✓ Amendment Transmittal Letter - 1 p.
- ✓ Certificate of Mailing by First Class Mail - 1 p.
- ✓ Courtesy Copy Preliminary Amendment filed March 8, 2001 - 5 pp.
- ✓ Revocation, Power of Attorney - 2 pp.

Attorney PBS / KMG

Director of the USPTO

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): LAM et al.

Docket No.

ARC 2865N1

Serial No.
09/802,709

Filing Date
03/08/01

Examiner
Z. Fay

Group Art Unit
1614

Invention:

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900



I hereby certify that this Revocation, Power of Attorney
Amendment Transmittal Letter, Courtesy Copy Prelim. Amend.
Response to Amendment, Acknowledgement Postcard, Request for Extension of Time
(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to: The
Assistant Commissioner for Patents, Washington, D.C. 20231 on November 28, 2001
(Date)

Katrina M. Ghafghaichi

(Typed or Printed Name of Person Mailing Correspondence)

Katrina M. Ghafghaichi
(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
ARC 2865N1

In Re Application Of: Lam et al.

Serial No.
09/802,709

Filing Date
03/08/01

Examiner
Z. Fay

Group Art Unit
1614

Title: METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Response to Amendment
Request for Extension of Time
Acknowledgement Postcard
Certificate of Mailing by First Class
Courtesy copy Prelim. Amendment filed March 8, 2001; Revocation, Power of Attorney

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☐ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Dated: 29 NOV 2001


Signature

I certify that this document and fee is being deposited
11/29/01 with the U.S. Postal Service as
class mail under 37 C.F.R. 1.8 and is addressed to
Assistant Commissioner for Patents, Washington,
20231.


Signature of Person Mailing Correspondence

Katrina M. Ghafghaichi
Typed or Printed Name of Person Mailing Correspondence

CC:

Amendment under 37 C.F.R. §1.111

LAM et al.

Serial No.: 09/802,709

Filed: March 08, 2001

For: METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

Extension of Time

A petition for a three-month extension of time and the fee therefore accompanies this response.

The Rejection Under 35 U.S.C. §103(a)

Claims 1-34 were rejected under 35 U.S.C. §103(a), as obvious over Dong et al. (U.S. Patent No. 5,770,227) and Patrick et al., Biopharmaceuticals & Drug Disposition, 10:165-171 (1989). To the extent the rejection may apply to claims 2 and 58-68, it is respectfully traversed.

Dong et al. relate to a therapeutic composition of progesterone for hormone replacement therapy (column 1, lines 10-16). Dong et al. employ two different tablet cores that are combined to prepare a dosage form for dispensing progesterone to the gastrointestinal tract of a human, (see for example, Example 7 of the specification). The dosage form may further contain an interior surface facing the dual core design and an exterior surface coated on its exterior surface having a semipermeable wall (Example 11). The dosage form may also contain an osmagent (Example 15).

Patrick et al. merely provide a perspective on the absorption of sustained-release methylphenidate formulations compared to immediate release formulations (page 165). This perspective is provided by comparing 3 products: a 10 mg tablet of MPH-IR Ritalin®, a 20 mg tablet of MPH-SR Ritalin®, and a newly formulated 20 mg tablet of MPH-SR from MD Pharmaceuticals (Santa Ana, Ca) (page 166). The authors concluded that the three formulations demonstrated were equivalent in the extent of absorption (page 170).

Applicants respectfully traverse this rejection for a number of reasons. Establishment of a *prima facie* case of obviousness requires that the cited documents teach or suggest all of the limitations of the rejected claims. In addition, some suggestion or motivation must be provided to modify the documents to reach the claimed invention. Further, a document must be

Amendment under 37 C.F.R. §1.111

LAM et al.

Serial No.: 09/802,709

Filed: March 08, 2001

For: METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

considered as a whole, including those portions of the document that teach away from the claimed invention.

Applicants respectfully submit that all of elements recited in claims 2 and 58-68 are not taught or suggested by Dong et al. and Patrick et al. Moreover, Applicants further submit that one of skill in the art would not be motivated to prepare a dosage form or methods as recited in Applicants' claims.

Dong et al. fail to teach or suggest any dosage form containing a single tablet core coated with a semipermeable membrane. Instead, Dong et al. employ two different tablet cores and combine these cores in a gelatin capsule. Moreover, Dong et al. is unrelated to a method for lessening the incidence of tolerance to methylphenidate to a patient or a method for treating attention deficient disorder in a patient.

Additionally, Dong et al. do not teach or suggest a dosage form that releases drug at a sustained and "increasing" dose as claimed by Applicants. Dong et al. merely provide an "acceptable oral means for administering progesterone at a controlled does over time," (column 1, lines 46-48). Moreover, Dong et al. fail to teach or suggest any dosage form having a single body core. Dong et al. relate only to combining two different tablet cores to prepare a dosage form. And, as pointed out by the Examiner, Dong et al. fail to teach or suggest a CNS acting drug, such as methylphenidate.

The secondary reference, Patrick et al., fails to supply that which is missing from Dong et al. Specifically, Patrick et al. merely provide a perspective on the absorption of sustained-release methylphenidate formulations compared to immediate release formulations. No teaching, suggestion or motivation is provided for the dosage forms and methods as claimed by Applicants.

For the above reasons, Applicants respectfully submit that the invention recited in claims 2 and 58-68 are patentable over Dong et al. in view of Patrick et al. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. §103(a) are respectfully requested.

Amendment under 37 C.F.R. §1.111

LAM et al.

Serial No.: 09/802,709


Filed: March 08, 2001

For: METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

Conclusion

In light of the remarks presented herein, it is respectfully submitted that pending claims 2 and 58-68 are in condition for allowance and notification to that effect is respectfully requested. The Examiner is invited to contact Applicants' Representative at the below-listed telephone number if it is believed that prosecution of this application may be assisted thereby.

Respectfully submitted,
LAM et al.,
By his Representatives,
ALZA Corporation
1900 Charleston Road
Mountain View, CA 94043
(650) 564-5000

By: 
Paul B. Simboli
Reg. No. 38,616
Attorney for Applicants
Direct Dial: (650) 564-7840

29 NOV 2001
Date

PBS/KMG



PATENT
Docket No. ARC 2865N1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lam et al.) Group Art Unit: 1614
Serial No.: 09/802,709) Examiner: Z. Fay
Filed: 03/08/2001)
For: Methods and Devices for Providing Prolonged Drug Therapy

REVOCATION, POWER OF ATTORNEY AND
CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Director of the USPTO
Washington, D.C. 20231

Dear Sir:

Please revoke any existing Power of Attorney, and appoint the following attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office in connection therewith:

Owen Bates
Pauline A. Clarke
Vandana Date
John A. Dhuey
D. Byron Miller
Robert R. Neller
Paul B. Simboli
Samuel E. Webb

Reg. No. 40,436
Reg. No. 29,783
Reg. No. 38,675
Reg. No. 26,265
Reg. No. 30,661
Reg. No. 46,950
Reg. No. 38,616
Reg. No. 44,394

Please send all correspondence to the following address:

Attn: Paul B. Simboli
ALZA Corporation
1900 Charleston Road
Mountain View, CA 94039-7210

Revocation, Power of Attorney and Certificate Under 37 C.F.R. §3.73(b)
 Serial No. 09/802,709
 Filed: March 8, 2001


Title: Methods and Devices for Providing Prolonged Drug Therapy

ALZA Corporation a corporation organized and existing under and by virtue of the laws of the State of DELAWARE and having an office and place of business at 1900 Charleston Road, Mountain View, CA 94043, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors, for which a copy thereof is attached. I have reviewed all the documents in the chain of title of the patent application identified above and, to the best of my knowledge and belief, title is in the assignee identified above.

I am empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


June 14, 2001
 Date


 Signature

D. Byron Miller
 Typed or Printed Name

Assistant Secretary, ALZA Corporation
 Title

Preliminary Amendment
Serial No.: Unassigned
Filed: Herewith



Page 1

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

PATENT
Docket No. ARC2865N1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	LAM et al.)	Group Art Unit:	Unknown
)		
Serial No.:	Unassigned)	Examiner:	Unknown
	(Parent: 09/253,317))		
)		
Filed:	Herewith)		
	(Parent: February 19, 1999))		
)		
For:	METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY			

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
ATTN: Box Patent Application
Washington D.C. 20231

Sir:
Prior to taking up the above-identified patent application for examination, please amend the specification as follows:

In the Specification

✓ Please delete paragraph [0001] and insert therefore new paragraph [0001] as follows:

[0001] This application is a continuation of U.S. Application No. 09/253,317, filed February 19, 1999, which is a continuation-in-part of U.S. Application No. 09/070,666, filed April 30, 1998, which is a continuation of U.S. Application No. 08/910,593, filed July 31, 1997, which claims the benefit of U.S. Provisional Application Nos. 60/030,514 and 60/044,121, filed November 12, 1996 and April 22, 1997, respectively.

Preliminary Amendment
Serial No.: Unassigned
Filed: Herewith

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

In the Claims

Please cancel claims 1 and 3-47. ✓

Please add the new claims 48-58: ✓

48. A method for lessening the incidence of tolerance to methylphenidate administered to an Attention-Deficit Disorder patient who develops tolerance to methylphenidate, wherein the method comprises administering orally to the patient a dosage form tablet that delivers 100 ng to 500 mg of methylphenidate in a sustained and increasing dose over 16 hours to produce the intended effect.
49. A method for lessening the incidence of tolerance in a patient having Attention-Deficit Disorder, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of methylphenidate and a pharmaceutically acceptable carrier, that is administered in a sustained and increasing dose for lessening the incidence of tolerance in the patient.
50. A method for treating Attention-Deficit Disorder in a patient, wherein the method comprises administering a pharmaceutically acceptable composition comprising 100 ng to 500 mg of a member selected from the group consisting of amphetamine, dextroamphetamine, methamphetamine, phenylisopropylamine, and pemoline, and a pharmaceutically acceptable carrier, in a sustained and increasing dose for treating Attention-Deficit Disorder in the patient.
51. A method for maintaining the therapeutic effect of methylphenidate in an Attention-Deficit Disorder patient who acquires tolerance to methylphenidate, wherein the method comprises administering orally to the patient a dosage form tablet comprising 100 ng to 500 mg of methylphenidate that delivers the methylphenidate in a controlled and increasing dose over 16 hours to maintain the therapeutic effect in the patient.

Preliminary Amendment
Serial No.: Unassigned
Filed: Herewith

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

52. A method for compensating for a decrease in the therapeutic effect to methylphenidate in an Attention-Deficit Disorder patient, wherein the method comprises administering a dosage form tablet comprising 100 ng to 500 mg of methylphenidate to the patient that administers the methylphenidate in a continually-ascending rate over 16 hours to compensate for the decrease in the therapeutic effect.

53. A method for treating Attention-Deficit Disorder in a human, wherein the method comprises administering orally to a human having Attention-Deficit Disorder a dosage form that administers a sustained and continuously ascending dose of 100 ng to 500 mg.

54. A method of treating Attention-Deficit Disorder in a human wherein the method comprises administering orally to a human having Attention-Deficit Disorder a dosage form that administers a sustained and continuously ascending dose of 5 mg to 75 mg over 12 hours of a drug selected from the group consisting of methylphenidate and its pharmaceutically acceptable salts for treating Attention-Deficit Disorder in the human.

55. A method of treating Attention-Deficit Disorder in a human, wherein the method comprises administering orally to a human having Attention-Deficit Disorder a dosage form that administers a sustained and continuously ascending dose of 100 ng to 500 mg over 16 hours of a drug selected from the group consisting of amphetamine, dextroamphetamine, methamphetamine, threomethylphenidate, phenylisopropylamine, and pemoline for treating Attention-Deficit Disorders in the human.

56. A method for the management of Attention-Deficit Disorder and Attention-Deficit Hyperactivity disorder in a patient, wherein the method comprises administering orally to the patient a dosage form comprising 100 ng to 500 mg of methylphenidate that is administered in a sustained and continuously ascending dose throughout a school day for the management of Attention-Deficit Disorder and Attention Deficit Hyperactivity Disorder in the patient.

Preliminary Amendment
Serial No.: Unassigned
Filed: Herewith

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

57. A dosage form tablet for treating Attention-Deficit Disorder comprising 100 ng to 500 mg of methylphenidate in admixture with a pharmaceutically acceptable carrier that release the methylphenidate in a sustained and increasing dose for treating Attention-deficit Disorder.

58. A dosage form tablet for treating Attention-Deficit Hyperactivity Disorder, comprising 100 ng to 500 mg of a member selected from the group consisting of methylphenidate and its pharmaceutically acceptable salts mixed with a pharmaceutically acceptable carrier that is delivered in a controlled and increasing dose for treating Attention-Deficit Hyperactivity Disorder.

REMARKS

The specification has been amended, i.e., paragraph [0001], to claim priority to parent application, U.S. Application No. 09/253,317.

Claims 1 and 3-47 have been canceled and claims 48-58 have been added. Upon entry of the Preliminary Amendment, claims 2 and 48-58 should be pending in the above-identified patent application.

Applicants bring to the Examiner's attention withdrawn U.S. Patent No. 6,034,101 (courtesy copy enclosed herewith). The claims previously allowed in U.S. Patent No. 6,034,101 (claims 1-11), are the claims now presented by preliminary amendment. This application claims priority to this withdrawn patent, i.e., U.S. Application No. 08/910,593, filed July 31, 1997.

No new matter has been added by these amendments.

Preliminary Amendment
Serial No.: Unassigned
Filed: Herewith

Page 5

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

The Examiner is invited to contact Applicants' Representatives, at the below-listed telephone number, if there are any questions regarding the above new claims or if prosecution of this application may be assisted thereby.

Respectfully submitted,
LAM et al.,
By his Representatives,
ALZA Corporation
1900 Charleston Road
Mountain View, CA 94043
(650) 564-5000

08 March 2001
Date

PBS/KMG

By: Paul B. Simboli
Paul B. Simboli
Reg. No. 38,616
Attorney for Applicants
Direct Dial: (650) 564-7840



Amendment under 37 C.F.R. §1.111

LAM et al.

LAM et al.
Serial No.: 09/802,709
March 08, 2001

Serial No.: 0978027
Filed: March 08, 2001
METHODS AND

AMENDED
LAM et al.
Serial No.: 09/802,709
Filed: March 08, 2001
For: METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

PATENT
Docket No. ARC2865N1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): LAM et al.

Serial No.: 09/802,709

Filed: 08 March 2001

Group Art Unit: 1614

Examiner: Z. Fay

Filed: 08 March 2001)
)
For: METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY
SER. 81111

AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

In response to the Office Action mailed 29 May 2001, Applicants submit the following:

Remarks

Remarks

Applicants wish to point out to the Examiner that a preliminary amendment was filed with the above-identified patent application on 08 March 2001. In the preliminary amendment, claims 1 and 3-47 were canceled and claims 58-68 were added. Thus, claims 2 and 58-68 are currently pending in the present application, not claims 1-34 as indicated in the current Office Action (a courtesy copy of the preliminary amendment is submitted herewith).

will address the rejections as they apply to the present pending claims.

of the preceding amendments and

Applicants will address the rejections as they apply to the present pending claims. Reconsideration and withdrawal of the rejections in light of the preceding amendments and following remarks are respectfully requested.



PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) (Large Entity)	Docket No. ARC 2865N1
--	--

In Re Application Of:

Lam et al.

Serial No. 09/802,709	Filing Date 03/08/01	Examiner Z. Fay	Group Art Unit 1614
---------------------------------	--------------------------------	---------------------------	-------------------------------

Invention:

METHODS AND DEVICES FOR PROVIDING PROLONGED DRUG THERAPY

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of May 29, 2001 in the above-identified application.
Date

The requested extension is as follows (check time period desired):

☐ One month ☐ Two months ☒ Three months ☐ Four months ☐ Five months

from: August 29, 2001

Date

until: November 29, 2001

Date

The fee for the extension of time is \$950 and is to be paid as follows:

- ☐ A check in the amount of the fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. 01-1173
A duplicate copy of this sheet is enclosed.
- ☐ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 01-1173
A duplicate copy of this sheet is enclosed.


Signature

Dated: November 29, 2001

I certify that this document and fee is being deposited on 11/29/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Signature of Person Mailing Correspondence

Katrina M. Ghafghaichi

Typed or Printed Name of Person Mailing Correspondence

CC:



1614

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/802,709
	Filing Date	March 8, 2001
	First Named Inventor	Andrew C. Lam
	Group Art Unit	1614
	Examiner Name	FAY, Z.
Total Number of Pages in This Submission	Attorney Docket Number	ARC 2865N1

TECH CENTER 1600/2800

RECEIVED
JUN 24 2002

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1- Return Receipt Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	2- Letter (2 pages)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	3- copies of original documents mailed to the USPTO on 11/29/2001 (16 pages)
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Robert R. Neller; Registratin No.: 46,950; ALZA Corporation
Signature	
Date	May 24, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 5-24-02			
Typed or printed name	Maria E. Valenzuela		
Signature		Date	May 24, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.